Captor Therapeutics lands $2M Michael J. Fox Foundation grant for Parkinson's candidate
What's the deal? Captor TherapeuticsDealroom has a profile for this one. Try Dealroom → has secured a $2 million non-dilutive grant from The Michael J. Fox Foundation for its NEK7 project, the Warsaw-listed biotech said on September 29, 2026. The award supports research into a brain-penetrant candidate for neurodegenerative diseases, including Parkinson's.
Why non-dilutive matters: The grant adds capital without a share issue or convertible debt, and Captor keeps the intellectual property rights tied to the NEK7 project. For a clinical-stage company, that is funding without a cost to existing shareholders.
What the numbers show: Captor reported a net loss of US$5.69M for the first half of 2026, up from US$5.12M a year earlier. It held US$17.9M in cash and investments at the end of the period, with runway projected through the third quarter of 2027.
Why now? The grant follows a March 3, 2026 sale of 800,000 Series Y shares at US$20.5 each. With the widening loss, funding duration and pipeline execution — rather than revenue — sit at the center of the investment case.
What's next? Captor is scheduled to publish third-quarter results on November 19, 2026. The grant extends runway, but the reported loss shows clinical development continues to consume capital.
The signal: At $2 million, this is a modest round by venture standards, but foundation grants carry weight for drug developers: they validate a program's scientific case while preserving equity. For a loss-making biotech, that trade-off — credibility plus cash, no dilution — is increasingly the point.
Read more: ad-hoc-news.de
Image credit: Captor Therapeutics
